Why does your "partner" not just buy out RVX? 

The FDA will want more than one SGLT2 drugs in the standard of care protocol for the next Phase 3; won't that cause a competitive tension of its own...if say LLY gets their Jardiance into this trail, they can always have a second (very weak) SGLT2 drug in the mix to satisfy the FDA.  Too much profits in those SGLT2 drugs for this one trial to be allowed to get a strong SGLT2 drug in.

IMHO, if we get any partnership, this stock is dead money at maybe $1.33 to $2.  There will be no interest in many of us entertaining yet more delays from RVX.  To wait another 3 years is beyond the interest of most investors.  

Iconoclast